COLL logo

COLL
Collegium Pharmaceutical Inc

1,591
Mkt Cap
$1.12B
Volume
4.00
52W High
$50.79
52W Low
$28.34
PE Ratio
16.85
COLL Fundamentals
Price
$34.42
Prev Close
$34.22
Open
$33.90
50D MA
$34.31
Beta
0.57
Avg. Volume
488,568.48
EPS (Annual)
$1.73
P/B
3.57
Rev/Employee
$1.85M
$2,368.09
Loading...
Loading...
News
all
press releases
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
News Placeholder
More News
News Placeholder
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
News Placeholder
Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on...
News Placeholder
Equities Analysts Offer Predictions for COLL Q2 Earnings
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Collegium Pharmaceutical in a...
News Placeholder
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...
News Placeholder
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 4.6% - Here's What Happened
Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 4.6% - Here's Why...
News Placeholder
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
Collegium Pharmaceutical (NASDAQ:COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham & Company's 25th Annual...
News Placeholder
Massachusetts Financial Services Co. MA Increases Stock Position in Collegium Pharmaceutical, Inc. $COLL
Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 65.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,312,655 shares of...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available